Every DEF 14A that Aspire-Lakewood Holdings, Inc. (ASBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ASBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASBP filings page.
Aspire Biopharma Holdings, Inc. is soliciting stockholder approval at a June 9, 2026 special meeting to ratify a Warrant Agreement with its financial advisor and related adjustments tied to issued pre-funded warrants.
The proposals seek (1) authorization to issue the Warrants and Warrant Shares (including shares in excess of 19.99%), (2) approval of formula-based adjustments to the number of shares issuable under the Warrants, (3) approval to permit voluntary reductions of the Warrants’ nominal exercise price of $0.00001 per share, and (4) authority to adjourn the meeting to solicit additional proxies if needed. The Board recommends a vote FOR all proposals. The record date is April 13, 2026, and shares outstanding were 5,024,142 as of that date.
Aspire Biopharma Holdings, Inc. is calling a June 9, 2026 special meeting to seek stockholder approval for several warrant-related actions tied to a financial advisory agreement and the acquisition of Direct Control Systems.
The key proposal asks stockholders to approve, for Nasdaq Rule 5635(d) purposes, the issuance of pre-funded warrants and the common shares issuable upon exercise, including any Warrant Shares above 19.99% of common stock outstanding on April 2026 at a nominal exercise price of $0.00001 per share. Additional proposals would authorize adjustments to the number of shares underlying the warrants under Section 3.2 of the Warrant Agreement, permit voluntary reductions of the warrant exercise price under Section 3.8, and allow adjournments of the meeting to gather more votes if needed. The Board recommends voting “FOR” all four proposals. Stockholders of record as of April 13, 2026, when 5,024,142 common shares were outstanding, are entitled to vote.
Aspire Biopharma Holdings, Inc. is calling a special stockholder meeting on April 10, 2026 to approve several capital structure and financing actions. The Board seeks authority for a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-500, to help maintain Nasdaq listing and potentially support liquidity.
Stockholders are also asked to approve the issuance of common shares upon conversion of newly issued Series A Convertible Preferred Stock, including amounts above 19.99% of common shares outstanding on February 6, 2026, and to approve a floor conversion price set at 20% of the Nasdaq-defined Minimum Price. A separate proposal would approve issuing 20% or more of outstanding common stock under a $100,000,000 equity line (ELOC Agreement) with Arena Business Solutions Global SPC II, Ltd., and another would increase authorized common shares from 490,000,000 to 700,000,000. As of February 11, 2026, 5,024,142 common shares were outstanding.